Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + rituximab + ifosfamide + carboplatin + etoposide
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Pola-R-ICE is an experimental chemoimmunotherapy combination regimen being evaluated as a salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant (ASCT). The regimen consists of the antibody-drug conjugate polatuzumab vedotin added to the standard-of-care R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) backbone. Polatuzumab vedotin targets CD79b, a component of the B-cell receptor, delivering the cytotoxic payload monomethyl auristatin E (MMAE) directly to malignant B cells. This combination aims to improve complete response rates and progression-free survival compared to R-ICE alone in the second-line setting. The Phase III trial (NCT04662255) investigating this regimen is sponsored by GWT-TUD GmbH.
- Other names
- Polatuzumab vedotin plus R-ICEPola-RICE
02
Targets
CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chainDNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on polatuzumab vedotin + rituximab + ifosfamide + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + rituximab + ifosfamide + carboplatin + etoposide.